Abstract
An intention-to-treat prospective randomized study was carried out to compare the potentiation of antiviral efficacies between cholecalciferol, non-activated vitamin D3 supplement, and alfacalcidol, activated 1α-Hydroxyvitamin D3 [1α (OH)-vitamin D3]. Chronic hepatitis patients with genotype 1b hepatitis C virus (HCV) infection showing serum HCV-RNA levels greater than 5 Log IU/mL received oral administration of cholecalciferol (2000 IU/day) or alfacalcidol (0.5 μg/day) for 4 weeks, and then they were given pegylated interferon (Peg-IFN)-α2a plus ribavirin therapy in combination with either vitamin D3 for 48 or 72 weeks according to the response-guided manner. A total of 36 patients were evaluated. Serum 25-hydroxyvitamin D3 [25(OH)-D3] levels were increased only in patients in the cholecalciferol group during the lead-in vitamin D administration, and the levels at 4 weeks were higher in these patients than in those in the alfacalcidol group (P < 0.001), while serum 1α,25-dihydroxyvitamin D3 [1α,25(OH)2 -D3] levels were not different between both groups. Rapid virological response was obtained in six (33%) patients in the cholecalciferol group; the ratio was higher than that in the alfacalcidol group (one patient; 6%, P < 0.05)...Continue Reading
References
Jul 20, 2007·The New England Journal of Medicine·Michael F Holick
Nov 9, 2007·The New England Journal of Medicine·Roger BouillonPaul Lips
Aug 12, 2008·The American Journal of Clinical Nutrition·Bruce W Hollis
Jan 20, 2009·Journal of Medical Virology·Norio AkutaHiromitsu Kumada
Sep 15, 2009·Nature Genetics·Yasuhito TanakaMasashi Mizokami
Apr 30, 2010·Current Opinion in Pharmacology·Femke BaekeChantal Mathieu
Dec 2, 2010·The Journal of Clinical Endocrinology and Metabolism·A Catharine RossSue A Shapses
Jun 8, 2011·The Journal of Clinical Endocrinology and Metabolism·Michael F HolickUNKNOWN Endocrine Society
Jul 28, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Meital Gal-TanamyRomy Zemel
Dec 2, 2011·Journal of Bone and Mineral Metabolism·Itsuo GoraiYasuhisa Iwaoki
Jan 5, 2012·World Journal of Gastroenterology : WJG·Saif Abu-MouchNimer Assy
Mar 1, 2012·World Journal of Gastroenterology : WJG·Assy Nimer, Abu Mouch
Apr 11, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Takuya MatsumuraMichio Imawari
May 30, 2013·PloS One·Yasuteru KondoTooru Shimosegawa
Jul 17, 2013·Nutrients·Barbara PrietlKarin Amrein
Jan 10, 2014·Hepatitis Monthly·Masanori AtsukawaChoitsu Sakamoto
Apr 9, 2014·PloS One·Shan-shan SuJun Yu
Apr 11, 2014·Journal of Viral Hepatitis·S YokoyamaK Chayama
May 3, 2014·PloS One·Amy E L StoneHugo R Rosen
Jun 2, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Masanori AtsukawaChoitsu Sakamoto
Citations
Aug 5, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Tomomi OkuboKatsuhiko Iwakiri
Mar 23, 2017·BMJ Open Gastroenterology·Noemi Hernández-AlvarezManuel Hernández-Guerra
Jul 12, 2016·Medicine·Xin-Yan ZhaoJi-Dong Jia
Apr 18, 2018·European Journal of Gastroenterology & Hepatology·Chao-Nan JinJi-Fang Sheng
Nov 27, 2015·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takuya MatsumuraTakanobu Kato
Apr 3, 2020·Nutrients·Choongho Lee
Aug 26, 2021·The Cochrane Database of Systematic Reviews·Milica BjelakovicChristian Gluud